Abstract
Autism is a severe childhood disorder already presenting in the first 3 years of life and, therefore, strongly correlated with neurodevelopmental alterations in prenatal, as well as postnatal period. Neurotransmitters hold a pivotal role in development by providing the stimulation needed for synapses and neuronal networks to be formed during the critical period of neuroplasticity. Aberrations of the serotonergic system modify key processes in the developing brain and are strongly implicated in the pathophysiology of developmental disorders. Evidence for the role of serotonin in autism emerges from neuropathological, imaging and genetic studies. Due to its developmental arrest, autism requires early intervention that would, among others, target the disrupted serotonergic system and utilize brain plasticity to elicit clinically important brain changes in children.
Keywords: Autism, serotonin, serotonergic, developmental intervention, plasticity, 5-hydroxytryptophan
Current Neuropharmacology
Title: The Serotonergic System: Its Role in Pathogenesis and Early Developmental Treatment of Autism
Volume: 7 Issue: 2
Author(s): D. I. Zafeiriou, A. Ververi and E. Vargiami
Affiliation:
Keywords: Autism, serotonin, serotonergic, developmental intervention, plasticity, 5-hydroxytryptophan
Abstract: Autism is a severe childhood disorder already presenting in the first 3 years of life and, therefore, strongly correlated with neurodevelopmental alterations in prenatal, as well as postnatal period. Neurotransmitters hold a pivotal role in development by providing the stimulation needed for synapses and neuronal networks to be formed during the critical period of neuroplasticity. Aberrations of the serotonergic system modify key processes in the developing brain and are strongly implicated in the pathophysiology of developmental disorders. Evidence for the role of serotonin in autism emerges from neuropathological, imaging and genetic studies. Due to its developmental arrest, autism requires early intervention that would, among others, target the disrupted serotonergic system and utilize brain plasticity to elicit clinically important brain changes in children.
Export Options
About this article
Cite this article as:
Zafeiriou I. D., Ververi A. and Vargiami E., The Serotonergic System: Its Role in Pathogenesis and Early Developmental Treatment of Autism, Current Neuropharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157015909788848848
DOI https://dx.doi.org/10.2174/157015909788848848 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
Central Nervous System Agents in Medicinal Chemistry A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry β-Secretase as a Therapeutic Target for Inhibitor Drugs
Current Medicinal Chemistry Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Are We There Yet? The Clinical Potential of Intranasal Oxytocin in Psychiatry
Current Psychiatry Reviews Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Sleep and Asthma
Current Respiratory Medicine Reviews The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Current Pharmaceutical Design COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice
Current Hypertension Reviews Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets The-N-End Rule: The Beginning Determines the End
Protein & Peptide Letters Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry Immunomodulatory Gene Therapy in Lysosomal Storage Disorders
Current Gene Therapy Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design Clinical Determination of the Severity of Metabolic Syndrome: Preheparin Lipoprotein Lipase Mass as a New Marker of Metabolic Syndrome
Current Medicinal Chemistry - Cardiovascular & Hematological Agents